Search
Technetium Tc-99m disofenin
go.drugbank.com/drugs/DB09164ApprovedWithdrawnIt is available as an intravenous injection in a preparation kit under the name Hepatolite. … Technetium Tc-99m disofenin is a radiopharmaceutical agent used in hepatobiliary imaging for diagnostic purposes.
Categories: Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 12f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10331ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 12f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 12f of *Streptococcus pneumoniae
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Streptococcus pneumoniae type 17f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10334ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 17f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 17f of *Streptococcus pneumoniae
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheEnalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalEnalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. … Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II.
Categories: Agents Acting on the Renin-Angiotensin SystemHydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedFDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy … Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999.[L46118] The U.S.
Synonyms: 17alpha-Caproyloxypregn-4-ene-3,20-dioneRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigationalHowever, it has a negligible effect on altering the development and progression of breast cancer itself. … Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] The approval covers adults and pediatric patients 8 years of age and older and was based on a statistically significant reduction in daily cornstarch intake, a surrogate endpoint, with … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalWhile [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens … Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function